Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ATM |
| Variant | Q628Pfs*7 |
| Impact List | frameshift |
| Protein Effect | loss of function - predicted |
| Gene Variant Descriptions | ATM Q628Pfs*7 indicates a shift in the reading frame starting at amino acid 628 and terminating 7 residues downstream causing a premature truncation of the 3056 amino acid Atm protein (UniProt.org). Q628Pfs*7 has not been characterized, however, due to the effects of other truncation mutations downstream of Q628 (PMID: 16603769), is predicted to lead to a loss of Atm protein function. |
| Associated Drug Resistance | |
| Category Variants Paths |
ATM mutant ATM inact mut ATM Q628Pfs*7 |
| Transcript | NM_000051.4 |
| gDNA | chr11:g.108252896dupC |
| cDNA | c.1882dupC |
| Protein | p.Q628Pfs*7 |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_000051.3 | chr11:g.108252896dupC | c.1882dupC | p.Q628Pfs*7 | RefSeq | GRCh38/hg38 |
| XM_005271562.5 | chr11:g.108252896dupC | c.1882dupC | p.Q628Pfs*7 | RefSeq | GRCh38/hg38 |
| XM_017017790.3 | chr11:g.108252896dupC | c.1882dupC | p.Q628Pfs*7 | RefSeq | GRCh38/hg38 |
| XM_011542840.3 | chr11:g.108252896dupC | c.1882dupC | p.Q628Pfs*7 | RefSeq | GRCh38/hg38 |
| XM_006718843.5 | chr11:g.108252896dupC | c.1882dupC | p.Q628Pfs*7 | RefSeq | GRCh38/hg38 |
| XM_005271562.6 | chr11:g.108252896dupC | c.1882dupC | p.Q628Pfs*7 | RefSeq | GRCh38/hg38 |
| XM_017017790.2 | chr11:g.108252896dupC | c.1882dupC | p.Q628Pfs*7 | RefSeq | GRCh38/hg38 |
| NM_000051.4 | chr11:g.108252896dupC | c.1882dupC | p.Q628Pfs*7 | RefSeq | GRCh38/hg38 |
| XM_017017792.2 | chr11:g.108252896dupC | c.1882dupC | p.Q628Pfs*7 | RefSeq | GRCh38/hg38 |
| NM_001351834.1 | chr11:g.108252896dupC | c.1882dupC | p.Q628Pfs*7 | RefSeq | GRCh38/hg38 |
| XM_047426981.1 | chr11:g.108252896dupC | c.1882dupC | p.Q628Pfs*7 | RefSeq | GRCh38/hg38 |
| XM_047426976.1 | chr11:g.108252896dupC | c.1882dupC | p.Q628Pfs*7 | RefSeq | GRCh38/hg38 |
| XM_017017791.1 | chr11:g.108252896dupC | c.1882dupC | p.Q628Pfs*7 | RefSeq | GRCh38/hg38 |
| NM_001351834.2 | chr11:g.108252896dupC | c.1882dupC | p.Q628Pfs*7 | RefSeq | GRCh38/hg38 |
| XM_011542843.3 | chr11:g.108252896dupC | c.1882dupC | p.Q628Pfs*7 | RefSeq | GRCh38/hg38 |
| XM_047426975.1 | chr11:g.108252896dupC | c.1882dupC | p.Q628Pfs*7 | RefSeq | GRCh38/hg38 |
| XM_006718843.4 | chr11:g.108252896dupC | c.1882dupC | p.Q628Pfs*7 | RefSeq | GRCh38/hg38 |
| XM_011542840.4 | chr11:g.108252896dupC | c.1882dupC | p.Q628Pfs*7 | RefSeq | GRCh38/hg38 |
| XM_011542843.2 | chr11:g.108252896dupC | c.1882dupC | p.Q628Pfs*7 | RefSeq | GRCh38/hg38 |
| XM_017017789.2 | chr11:g.108252896dupC | c.1882dupC | p.Q628Pfs*7 | RefSeq | GRCh38/hg38 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|